Alumis Inc Stock Price, News & Analysis

Alumis (Nasdaq: ALMS) reported Q2 2025 financial results and significant clinical progress. The company completed enrollment in two major trials: the Phase 3 ONWARD trials for envudeucitinib in plaque psoriasis (topline data expected Q1 2026) and the Phase 2b LUMUS trial for systemic lupus erythematosus (topline data expected Q3 2026).

Key financial highlights include $486.3 million in cash and equivalents, expected to fund operations into 2027. Q2 revenue was $2.7 million from the Kaken Pharmaceutical collaboration. The company reported a net income of $59.3 million, including a $187.9 million gain from the ACELYRIN merger.

R&D expenses increased to $108.8 million (vs $48.6M in Q2 2024), while G&A expenses rose to $34.5 million (vs $7.6M in Q2 2024). The merger with ACELYRIN added $382.6 million to the company's cash position.

Alumis (Nasdaq: ALMS) has completed patient enrollment in its global LUMUS Phase 2b trial for ESK-001, a next-generation oral TYK2 inhibitor targeting systemic lupus erythematosus (SLE). The trial has enrolled 408 patients who will receive ESK-001 or placebo for 48 weeks.

The study will evaluate the drug's efficacy in treating moderately-to-severely active, autoantibody-positive SLE, with topline data expected in Q3 2026. The primary endpoint will measure disease activity improvements using the BICLA assessment at Week 48. The company reports that ESK-001 has shown promising results in their psoriasis program, demonstrating full target inhibition and general tolerability.

Alumis (Nasdaq: ALMS), a late-stage biopharma company focused on immune-mediated diseases, has promoted Sanam Pangali to Chief Legal Officer and Corporate Secretary. Pangali, who previously served as Senior Vice President, Legal at Alumis, succeeds Sara Klein following her retirement.

In her new role, Pangali will oversee all legal and compliance functions, including corporate governance, intellectual property, and strategic advisory. She brings significant experience from her previous positions at ACELYRIN, Snapdocs, and Principia Biopharma, where she held senior legal roles. Her background includes leading legal affairs through significant corporate events, including IPOs and mergers.

Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's President and CEO, Martin Babler, will deliver a presentation on June 4, 2025, at 3:10 p.m. ET. Interested parties can access a live webcast of the presentation through the "Investors" section of the Alumis website, under the "Events" page. The webcast recording will remain available for replay on the company's website for 90 days following the event.

Alumis Inc. (ALMS) has completed patient enrollment in its pivotal Phase 3 ONWARD clinical program evaluating ESK-001, a next-generation oral TYK2 inhibitor, for treating moderate-to-severe plaque psoriasis. The program includes two parallel Phase 3 trials with over 1,700 patients enrolled, with topline results expected in early Q1 2026. ESK-001 aims to address current treatment challenges by offering a well-tolerated oral alternative to injectable biologics, potentially delivering durable, biologic-like clinical responses. The ONWARD program consists of ONWARD1 and ONWARD2 (24-week trials), plus ONWARD3, an optional long-term extension trial to assess durability and safety.

Alumis Inc. (NASDAQ: ALMS) has completed its merger with ACELYRIN, Inc., creating a leading clinical-stage biopharma company focused on immune-mediated diseases. Under the merger terms, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each ACELYRIN share. ACELYRIN's stock has been delisted from NASDAQ.

The merger significantly strengthens Alumis' balance sheet, extending its cash runway into 2027. The combined company aims to advance its late-stage portfolio through multiple planned key data readouts. Morgan Stanley advised Alumis, while Guggenheim Securities advised ACELYRIN in the transaction.

Alumis (NASDAQ: ALMS) reported its Q1 2025 financial results and key developments. The company ended Q1 with $208.7 million in cash and equivalents. Revenue included $17.4 million from Kaken Pharmaceutical licensing agreement. Net loss widened to $99.0 million compared to $49.8 million in Q1 2024. R&D expenses increased to $96.6 million from $42.0 million YoY. The company is progressing toward a merger with ACELYRIN, expected to close in Q2 2025, with Alumis stockholders owning 52% of the combined entity. The merged company will have a pro forma cash position of $737 million, providing runway into 2027. Key pipeline developments include anticipated Phase 3 topline data for ESK-001 in psoriasis (Q1 2026) and Phase 2b data in systemic lupus erythematosus (2026).

Alumis Inc. (ALMS) stockholders have approved all proposals necessary for the pending merger with ACELYRIN, INC. (SLRN). The merger, announced at a Special Meeting of Stockholders, is expected to close in Q2 2025, subject to customary closing conditions. CEO Martin Babler expressed gratitude for stockholder support and highlighted that the merger would strengthen the company's financial foundation to advance breakthroughs in immune-mediated diseases. Alumis will file the final voting results in a Form 8-K with the SEC.

Alumis (NASDAQ: ALMS) and ACELYRIN have announced an amended merger agreement with revised ownership terms. Under the new agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each ACELYRIN share, resulting in Alumis stockholders owning approximately 52% and ACELYRIN stockholders owning 48% of the combined company.

The merger aims to create a leading clinical-stage immunology company with enhanced financial flexibility. The combined entity will have a pro forma cash position of approximately $737 million as of December 31, 2024, with funding expected to last into 2027. The transaction has received unanimous approval from both companies' boards, with stockholder voting agreements already secured from 62% of Alumis and 24% of ACELYRIN shareholders.

Special stockholder meetings are scheduled for May 13, 2025, with the transaction expected to close in Q2 2025, subject to stockholder approval and customary closing conditions.